13 studies found for:    J591
Show Display Options
Rank Status Study
1 Recruiting 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: 177Lu-J591;   Drug: Ketoconazole;   Drug: Hydrocortisone;   Drug: 111In-J591
2 Recruiting 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
Condition: Glioblastoma
Interventions: Drug: 89Zr-J591;   Device: PET/CT Scan;   Device: MRI;   Other: Blood draw
3 Active, not recruiting Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel;   Drug: Prednisone;   Drug: 177Lu-J591
4 Recruiting Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
Condition: Prostate Cancer
Intervention: Drug: 117Lu-J591
5 Recruiting Neoadjuvant J591 Treatment for Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: huJ591;   Drug: 89Zr−J591
6 Recruiting 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
7 Completed Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
8 Recruiting J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
Condition: Prostate Cancer
Intervention: Drug: huJ591
9 Completed Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
Condition: Prostatic Neoplasms
Interventions: Drug: Monoclonal Antibody J591;   Drug: Recombinant Interleukin-2
10 Completed Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate
Condition: Prostate Cancer
Intervention: Radiation: lutetium Lu 177 monoclonal antibody J591
11 Completed Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: monoclonal antibody huJ591
12 Completed Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: monoclonal antibody muJ591;   Radiation: iodine I 131 monoclonal antibody muJ591
13 Active, not recruiting Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 89Zr-DFO-huJ591

Indicates status has not been verified in more than two years